about
Fatty liver disease determines the progression of coronary artery calcification in a metabolically healthy obese population.Visceral adiposity index predicts the conversion of metabolically healthy obesity to an unhealthy phenotype.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.The Population-Based Risk of Need for Coronary Revascularization According to the Presence of Type 2 Diabetes Mellitus and History of Coronary Heart Disease in the Korean Population.Serum Ceruloplasmin Level as a Predictor for the Progression of Diabetic Nephropathy in Korean Men with Type 2 Diabetes Mellitus.Mortality and causes of death in a national sample of type 2 diabetic patients in Korea from 2002 to 2013The risk of incident type 2 diabetes in a Korean metabolically healthy obese population: the role of systemic inflammation.Effects of Incretin-Based Therapies on Diabetic Microvascular Complications.The optimal morning:evening ratio in total dose of twice-daily biphasic insulin analogue in poorly controlled Type 2 diabetes: a 24-week multi-centre prospective, randomized controlled, open-labelled clinical study.Comparison between sodium-glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta-analysis.Effect of SFRP5 (Secreted Frizzled-Related Protein 5) on the WNT5A (Wingless-Type Family Member 5A)-Induced Endothelial Dysfunction and Its Relevance With Arterial Stiffness in Human Subjects.Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trialAsian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome TrialsEffectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea
P50
Q33574490-1F70CE9A-B56A-4A41-879F-90E34E71155FQ33828903-8ED37CB9-BBE3-46F3-B1DE-1C0F4A70F066Q34161881-FB14EE39-842A-4B97-9370-A0EFDAB22369Q35656400-15A5CFF7-88A8-4326-AF2B-096C1D0440D3Q35790640-25BF554D-C3B4-41AA-8F22-483A384A375BQ37251203-0EED11CC-0F8A-41C8-8A45-FF7406FBC087Q41711625-92A54A22-79EA-42CE-A799-FFA883E1F117Q42366423-145B656F-E1D1-4789-9D6E-1640C6A2F9B9Q45391402-F2219F40-1FBD-42E6-BCD8-4AF8078ABCBEQ48160690-6FD9478E-9C40-4224-B4FF-E66112B21175Q53072773-CDD5E936-C8A6-429E-AABE-650751C31200Q57212554-F8B61E81-E3AC-4A6E-B514-06F94A3E6894Q90860464-7143D28C-CABE-420F-83D2-A8F386161B48Q93008530-F68209D6-42E1-4C2D-89E1-3A019A064F42
P50
description
researcher
@en
wetenschapper
@nl
name
Chang Hee Jung
@en
Chang Hee Jung
@nl
type
label
Chang Hee Jung
@en
Chang Hee Jung
@nl
prefLabel
Chang Hee Jung
@en
Chang Hee Jung
@nl
P108
P31
P496
0000-0003-4043-2396